Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Slides:

Advertisements

Similar presentations

An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer Takahiro Karasaki, MD, Kazuhiro Nagayama, MD, PhD, Hideki.

Advertisements

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape Hawazin Faruki,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Four nodes to target when inducing anti-tumour immunity

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Oncology Meets Immunology: The Cancer-Immunity Cycle

SC17.02 Lung Cancer in China: Challenges and Perspectives

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

Figure 4 Combination immunotherapeutic approaches with imatinib

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer Xiaomei Gong, MD, PhD, Xuefei Li,

Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC Christian Manegold, MD, Anne-Marie C. Dingemans,

Leonardo V. Riella, Mohamed H. Sayegh Kidney International Supplements

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Nat. Rev. Rheumatol. doi: /nrrheum

Electronic Updates for JTO Readers

Vamsidhar Velcheti, MD, David L. Rimm, MD, PhD, Kurt A

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Figure 1 The role of CTLA4 and PD1 in T cell activation

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Mechanisms of immune escape in the tumor microenvironment.

Volume 75, Issue 3, Pages (March 2019)

Frank Detterbeck, MD Journal of Thoracic Oncology

Alterations of the Immune System in Thymic Malignancies

Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival Tom Donnem,

Nat. Rev. Endocrinol. doi: /nrendo

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Figure 1 Mechanisms of action of immunotherapy modalities

Erratum Journal of Thoracic Oncology

Nat. Rev. Urol. doi: /nrurol

David C. Soler, Thomas S. McCormick

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Andy J. Minn, E. John Wherry Cell

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

Cell-mediated immunity Regulation of the immune response

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Vaccines for Lung Cancer

Padmanee Sharma, James P. Allison Cell

Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma Iris C. Salaroglio, PhD, Joanna Kopecka, PhD, Francesca.

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

A Review of First-Line Treatment for Small-cell Lung Cancer

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Robert Comis, MD, The Passing of a “Lung Man”

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Immune Biomarkers on the Radar—Comprehensive “Immunograms” for Multimodal Treatment Prediction Johan Botling, MD, PhD, Martin Sandelin, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 5, Pages 770-772 (May 2017) DOI: 10.1016/j.jtho.2017.03.009 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Representative immunograms of T-cell–poor (upper panel) and T-cell–rich (lower panel) NSCLC cases. The 8 axes in the radar plots illustrate the range of biomarker scores obtained for eight different immune parameters related to T-cell–mediated antitumor activities, as explained in the main text. The T-cell–poor case largely lacks immune suppressive traits (axes 6 to 8) but scores low on tumor antigen expression (axis 2), dendritic cell activation (axis 3), T-cell trafficking (axis 4), and antigen-presenting capabilities (axis 5). This patient could hypothetically benefit from candidate immune-stimulatory agents as indicated. The T-cell–rich case has an opposite pattern influenced by signs of inhibitory activities (axes 6 and 8) in addition to checkpoint molecule expression (axis 7). This patient might need treatments, in addition to programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1 inhibition), that counteract other immune-suppressive mechanisms. CTLA4, cytotoxic T-lymphocyte antigen 4; IFN-α, interferon-α; CAR-T, chimeric antigen receptor T; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cell; IDO1, indoleamine 2,3-dioxygenase 1. (Modified with permission from Karasaki et al.6) Journal of Thoracic Oncology 2017 12, 770-772DOI: (10.1016/j.jtho.2017.03.009) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions